274 related articles for article (PubMed ID: 26585210)
21. Targeting AR-Beclin 1 complex-modulated growth factor signaling increases the antiandrogen Enzalutamide sensitivity to better suppress the castration-resistant prostate cancer growth.
Zhang M; Sun Y; Meng J; Zhang L; Liang C; Chang C
Cancer Lett; 2019 Feb; 442():483-490. PubMed ID: 30423407
[TBL] [Abstract][Full Text] [Related]
22. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer.
Murga JD; Moorji SM; Han AQ; Magargal WW; DiPippo VA; Olson WC
Prostate; 2015 Feb; 75(3):242-54. PubMed ID: 25327687
[TBL] [Abstract][Full Text] [Related]
23. AKR1C3 Inhibitor KV-37 Exhibits Antineoplastic Effects and Potentiates Enzalutamide in Combination Therapy in Prostate Adenocarcinoma Cells.
Verma K; Gupta N; Zang T; Wangtrakluldee P; Srivastava SK; Penning TM; Trippier PC
Mol Cancer Ther; 2018 Sep; 17(9):1833-1845. PubMed ID: 29891491
[TBL] [Abstract][Full Text] [Related]
24. Intravenous delivery of enzalutamide based on high drug loading multifunctional graphene oxide nanoparticles for castration-resistant prostate cancer therapy.
Jiang W; Chen J; Gong C; Wang Y; Gao Y; Yuan Y
J Nanobiotechnology; 2020 Mar; 18(1):50. PubMed ID: 32188463
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract][Full Text] [Related]
26. The clinical benefit of sequential therapy with androgen receptor axis-targeted agents alone in patients with castration-resistant prostate cancer: A propensity score-matched comparison study.
Naito Y; Kato M; Kawanishi H; Yuguchi Y; Yuba T; Ishikawa T; Hattori K; Yamamoto A; Sano T; Matsukawa Y; Kimura T; Nishikimi T; Hattori R; Tsuzuki T; Gotoh M
Prostate; 2020 Nov; 80(15):1373-1380. PubMed ID: 32914895
[TBL] [Abstract][Full Text] [Related]
27. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.
Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A
Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401
[TBL] [Abstract][Full Text] [Related]
29. Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer.
Petrylak DP; Kantoff P; Vogelzang NJ; Mega A; Fleming MT; Stephenson JJ; Frank R; Shore ND; Dreicer R; McClay EF; Berry WR; Agarwal M; DiPippo VA; Rotshteyn Y; Stambler N; Olson WC; Morris SA; Israel RJ
Prostate; 2019 May; 79(6):604-613. PubMed ID: 30663074
[TBL] [Abstract][Full Text] [Related]
30. Upregulation of glucocorticoid receptor-mediated glucose transporter 4 in enzalutamide-resistant prostate cancer.
Hoshi S; Meguro S; Imai H; Matsuoka Y; Yoshida Y; Onagi A; Tanji R; Honda-Takinami R; Matsuoka K; Koguchi T; Hata J; Sato Y; Akaihata H; Kataoka M; Ogawa S; Kojima Y
Cancer Sci; 2021 May; 112(5):1899-1910. PubMed ID: 33619826
[TBL] [Abstract][Full Text] [Related]
31. Abiraterone Acetate and Enzalutamide: Similar Efficacy in Treating Post Docetaxel Metastatic Castration-resistant Prostate Cancer: Single Center Experience.
Chang LW; Hung SC; Wang SS; Li JR; Yang CK; Chen CS; Ho HC; Cheng CL; Ou YC; Chiu KY
Anticancer Res; 2019 Jul; 39(7):3901-3908. PubMed ID: 31262919
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic effects of human monoclonal PSMA antibody-mediated TRIM24 siRNA delivery in PSMA-positive castration-resistant prostate cancer.
Shi SJ; Wang LJ; Han DH; Wu JH; Jiao D; Zhang KL; Chen JW; Li Y; Yang F; Zhang JL; Zheng GX; Yang AG; Zhao AZ; Qin WJ; Wen WH
Theranostics; 2019; 9(5):1247-1263. PubMed ID: 30867828
[No Abstract] [Full Text] [Related]
33. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer.
Lückerath K; Wei L; Fendler WP; Evans-Axelsson S; Stuparu AD; Slavik R; Mona CE; Calais J; Rettig M; Reiter RE; Herrmann K; Radu CG; Czernin J; Eiber M
EJNMMI Res; 2018 Oct; 8(1):96. PubMed ID: 30374743
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
Perletti G; Monti E; Marras E; Cleves A; Magri V; Trinchieri A; Rennie PS
Arch Ital Urol Androl; 2015 Jul; 87(2):121-9. PubMed ID: 26150028
[TBL] [Abstract][Full Text] [Related]
35. Overall Survival Among Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer Under Abiraterone Versus Enzalutamide: A Direct Comparison Based on a 2014-2018 French Population Study (the SPEAR Cohort).
Scailteux LM; Campillo-Gimenez B; Kerbrat S; Despas F; Mathieu R; Vincendeau S; Balusson F; Happe A; Nowak E; Oger E
Am J Epidemiol; 2021 Feb; 190(3):413-422. PubMed ID: 32944756
[TBL] [Abstract][Full Text] [Related]
36. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance.
Barqawi YK; Borrego ME; Roberts MH; Abraham I
J Med Econ; 2019 Nov; 22(11):1202-1209. PubMed ID: 31452414
[No Abstract] [Full Text] [Related]
38. Targeting Prostate Cancer Subtype 1 by Forkhead Box M1 Pathway Inhibition.
Ketola K; Munuganti RSN; Davies A; Nip KM; Bishop JL; Zoubeidi A
Clin Cancer Res; 2017 Nov; 23(22):6923-6933. PubMed ID: 28899970
[No Abstract] [Full Text] [Related]
39. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
Wang R; Lin W; Lin C; Li L; Sun Y; Chang C
Cancer Lett; 2016 Aug; 379(1):154-60. PubMed ID: 27233475
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Alternative Androgen Receptor-axis-targeted Agent (ARATA) and Docetaxel as Second-line Therapy for Patients With Metastatic Castration-resistant Prostate Cancer With Progression After Initial ARATA in Real-world Clinical Practice in Japan.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Clin Genitourin Cancer; 2018 Jun; 16(3):219-225. PubMed ID: 29274813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]